Amarin Corp Plcuk (AMRN) Capital Expenditures (2010 - 2020)
Amarin Corp Plcuk (AMRN) posted quarterly Capital Expenditures of $1000.0 for Q3 2020, down 99.92% YoY from $1.3 million in Q4 2019, and down 99.6% sequentially from $251000.0 in Q1 2020.
Amarin Corp Plcuk (AMRN) Capital Expenditures (2010 - 2020) Analysis & Trends
Amarin Corp Plcuk has disclosed Capital Expenditures across 10 years of filings, most recently posting $1000.0 for Q3 2020.
- In Q3 2020, Capital Expenditures fell 99.92% year-over-year to $1000.0; the TTM figure through Dec 2020 stood at $252000.0 (down 85.02% YoY), while the FY2020 annual figure was $252000.0, down 89.83% from the prior year.
- Capital Expenditures retreated to $1000.0 in Q3 2020, from $251000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for AMRN reached as high as $1.3 million in Q3 2019 and fell as low as $1000.0 in Q3 2020.
- The 5-year median for Capital Expenditures is $21000.0 (2016), against an average of $281000.0.
- Annual changes were most pronounced in 2019 — Capital Expenditures soared 7180.0% — and 2020, when it slumped 99.92%.
- A 5-year view of Capital Expenditures shows it stood at $21000.0 in 2016, then sank by 42.86% to $12000.0 in 2017, then plunged by 58.33% to $5000.0 in 2018, then soared by 7180.0% to $364000.0 in 2019, then sank by 99.73% to $1000.0 in 2020.
- According to Business Quant data, Capital Expenditures over the past three periods registered $1000.0, $251000.0, and $364000.0 for Q3 2020, Q1 2020, and Q4 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 2.33 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 1.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 265.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -547.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 991.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 712.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 117.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 436.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -346.00 Mn |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 1,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Mar 31, 2020 | 251,000.00 |
| Mar 31, 2020 | 251,000.00 |
| Dec 31, 2019 | 364,000.00 |
| Dec 31, 2019 | 364,000.00 |
| Sep 30, 2019 | 1.31 Mn |
| Sep 30, 2019 | 1.31 Mn |
| Dec 31, 2018 | 5,000.00 |
| Dec 31, 2018 | 5,000.00 |
| Mar 31, 2017 | 12,000.00 |
| Mar 31, 2017 | 12,000.00 |
| Mar 31, 2016 | 21,000.00 |
| Mar 31, 2016 | 21,000.00 |
| Dec 31, 2015 | 18,000.00 |
| Dec 31, 2015 | 18,000.00 |
| Mar 31, 2013 | 14,000.00 |
| Mar 31, 2013 | 14,000.00 |
| Dec 31, 2012 | 72,000.00 |
| Dec 31, 2012 | 72,000.00 |